ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,996.66
      1.00%
      US Tech 100
      20,877.20
      1.72%
      Dow Jones
      43,487.83
      0.78%
      Brent Oil
      80.005
      0.00%
      Bitcoin
      104,542.65
      0.12%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX

      6. Channel Therapeutics Corporation (CHRO) Quote

      Channel Therapeutics Corporation

      Channel Therapeutics Corporation (CHRO)

      AMEX
      1.90
      0.94
      (97.92%)
      Closed January 19 4:00PM
      Delayed by 15 minutes
      2.06
      0.16
      (8.42%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      2.06
      Bid
      -
      Ask
      -
      Volume
      14,269,808
      1.00 Day's Range 2.45
      0.45 52 Week Range 6.00
      Market Cap
      12.418M
      Previous Close
      0.96
      Open
      1.09
      Last Trade
      4545
      @
      1.9
      Last Trade Time
      Financial Volume
      $ 24,062,439
      VWAP
      1.6862
      Average Volume (3m)
      109,880
      Shares Outstanding
      6,028,011
      Dividend Yield
      -
      PE Ratio
      -1.55
      Earnings Per Share (EPS)
      -1.22
      Revenue
      -
      Net Profit
      -7.38M

      About Channel Therapeutics Corporation

      Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      channeltherapeutics.com
      Headquarters
      Reno, Nevada, USA
      Founded
      -
      Channel Therapeutics Corporation is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CHRO. The last closing price for Channel Therapeutics was $0.96. Over the last year, Channel Therapeutics shares have traded in a share price range of $ 0.45 to $ 6.00.

      Channel Therapeutics currently has 6,028,011 shares outstanding. The market capitalization of Channel Therapeutics is $5.79 million. Channel Therapeutics has a price to earnings ratio (PE ratio) of -1.55.

      Ask ADVFN Intelligence (AI)

      CHRO Latest News

      More News

      Chromocell Announces Amendment to Stock Repurchase Plan

      FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      October 24 2024
      GlobeNewswire Inc.

      Chromocell to Participate in the Virtual Investor Lunch Break Series

      FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      July 15 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      June 18 2024
      Edgar (US Regulatory)

      Form 424B3 - Prospectus [Rule 424(b)(3)]

      May 15 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 15 2024
      Edgar (US Regulatory)

      Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024

      FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      May 13 2024
      GlobeNewswire Inc.

      Chromocell Issues Letter to Stockholders from Chief Executive Officer

      FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      April 09 2024
      GlobeNewswire Inc.

      Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

      FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      March 21 2024
      GlobeNewswire Inc.

      Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

      FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      March 18 2024
      GlobeNewswire Inc.

      Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

      AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...

      March 11 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      11.05103.960396041.012.060.811640490.9484076CS
      41.414218.8854489160.6462.060.5621159630.8437335CS
      121.339185.7142857140.7212.060.451098800.73445435CS
      260.8976.06837606841.172.060.451121050.79697305CS
      52-3.94-65.6666666667660.45726061.03918864CS
      156-3.94-65.6666666667660.45726061.03918864CS
      260-3.94-65.6666666667660.45726061.03918864CS

      CHRO - Frequently Asked Questions (FAQ)

      What is the current Channel Therapeutics share price?
      The current share price of Channel Therapeutics is $ 2.06
      How many Channel Therapeutics shares are in issue?
      Channel Therapeutics has 6,028,011 shares in issue
      What is the market cap of Channel Therapeutics?
      The market capitalisation of Channel Therapeutics is USD 5.79M
      What is the 1 year trading range for Channel Therapeutics share price?
      Channel Therapeutics has traded in the range of $ 0.45 to $ 6.00 during the past year
      What is the PE ratio of Channel Therapeutics?
      The price to earnings ratio of Channel Therapeutics is -1.55
      What is the reporting currency for Channel Therapeutics?
      Channel Therapeutics reports financial results in USD
      What is the latest annual profit for Channel Therapeutics?
      The latest annual profit of Channel Therapeutics is USD -7.38M
      What is the registered address of Channel Therapeutics?
      The registered address for Channel Therapeutics is 50 WEST LIBERTY STREET, SUITE 880, RENO, NEVADA, 89501
      What is the Channel Therapeutics website address?
      The website address for Channel Therapeutics is channeltherapeutics.com
      Which industry sector does Channel Therapeutics operate in?
      Channel Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CHROChannel Therapeutics Corporation
      $ 1.90
      (97.92%)
      		14.27M
      GPUSHyperscale Data Inc
      $ 4.60
      (22.99%)
      		215.83k
      VINEFresh Vine Wine Inc
      $ 0.6899
      (22.98%)
      		376.38k
      RHERegional Health Properties Inc
      $ 2.40
      (18.81%)
      		227.57k
      MSTUT Rex 2X Long MSTR Daily Target ETF
      $ 13.245
      (16.80%)
      		62.46M
      FOXOFOXO Technologies Inc
      $ 0.2295
      (-27.14%)
      		11.34M
      OSTXOS Therapies Incorporated
      $ 3.03
      (-26.46%)
      		1.63M
      AEONAEON Biopharma Inc
      $ 0.1401
      (-18.02%)
      		29.86M
      MSTZT Rex 2X Inverse MSTR Daily Target ETF
      $ 12.56
      (-16.32%)
      		26.3M
      BOILProShares Ultra Bloomberg Natural Gas New
      $ 67.43
      (-14.52%)
      		3.87M
      SOXLDirexion Daily Semiconductor Bull 3X Shares
      $ 32.49
      (8.34%)
      		69.69M
      MSTUT Rex 2X Long MSTR Daily Target ETF
      $ 13.245
      (16.80%)
      		62.46M
      FXIiShares China Large Cap
      $ 30.40
      (1.91%)
      		59.69M
      SPYSPDR S&P 500
      $ 597.58
      (1.00%)
      		57.17M
      SOXSDirexion Daily Semiconductor Bear 3X Shares New
      $ 18.33
      (-8.03%)
      		53.86M

      CHRO Discussion

      View Posts
      glenn1919 glenn1919 1 day ago
      CHRO............................https://stockcharts.com/h-sc/ui?s=CHRO&p=W&b=5&g=0&id=p86431144783
      👍️0

      Your Recent History

      AMEX
      CHRO
      Channel Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads